AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
San Francisco's Montara Therapeutics secures $20 million in seed funding to advance epilepsy drug development and explore ...
Zacks Investment Research on MSN8h
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should KnowAbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
AbbVie Inc. stands out as one of the top pharma stocks to buy, according to hedge funds. The company exceeded analyst ...
AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Berenberg raised AbbVie’s price target from $165 to $195 while maintaining a Hold rating. The firm increased its estimates due to stronger-than-expected immunology sales. AbbVie’s stock has surged 22% ...
REITs pay dividends out of their funds from operations (FFO), and Vici's FFO per share is $2.61 over the last 12 months. This ...
Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback